Open AccessHead-to-head clinical Trial of Sofosbuvir plus Daclatasvir or Simeprevir for 12 weeks in Non-cirrhotic subjects with significant fibrosis infected with chronic Hepatitis C Virus genoType 1 (TNT-1 Study)
Author(s) -
Henrique Pott,
Guilherme Bricks,
Giuliano Grandi,
Jorge Figueiredo Senise,
A. Castelo
Publication year - 2018
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2018.04.4264
Subject(s) - daclatasvir , sofosbuvir , simeprevir , medicine , gastroenterology , regimen , pegylated interferon , clinical endpoint , ribavirin , randomized controlled trial , adverse effect , hepatitis c virus , virology , virus
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom